Oxford BioMedica Total Assets 2020-2024 | OXBDF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Oxford BioMedica total assets from 2020 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Oxford BioMedica total assets from 2020 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$150.5B
Bristol Myers Squibb (BMY)	$118.1B
Vertex Pharmaceuticals (VRTX)	$115.4B
Gilead Sciences (GILD)	$109.4B
CSL (CSLLY)	$85.4B
Regeneron Pharmaceuticals (REGN)	$81.8B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$34.4B
Alnylam Pharmaceuticals (ALNY)	$30.2B
BioNTech SE (BNTX)	$25.5B
Biogen (BIIB)	$22.6B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$18.3B
Moderna (MRNA)	$14.3B
Incyte (INCY)	$13.6B
Genmab (GMAB)	$13.6B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.8B
Vaxcyte (PCVX)	$10.9B
Bio-Techne Corp (TECH)	$10.5B
Sarepta Therapeutics (SRPT)	$10.2B
Exact Sciences (EXAS)	$10B
Exelixis (EXEL)	$9.8B
Revolution Medicines (RVMD)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
QIAGEN (QGEN)	$9.3B
Intra-Cellular Therapies (ITCI)	$8.8B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$7.5B
Repligen (RGEN)	$7.2B